Evaluation of the effects of lecanemab treatment on brain atrophy using voxel-based specific regional analysis system for Alzheimer's disease - PubMed

6 hours ago

Lecanemab, a monoclonal antibody targeting amyloid-β (Aβ), reduces Aβ plaques and slows cognitive decline in Alzheimer's disease (AD) patients.
The study evaluated lecanemab's effect on brain structure using voxel-based specific regional analysis system for Alzheimer's disease (VSRAD) via MRI.
16 AD patients received four biweekly lecanemab doses (10 mg/kg); amyloid pathology was confirmed via PET and cerebrospinal fluid tests.
Post-treatment, medial temporal lobe (MTL) Z-scores significantly decreased from 1.61 ± 0.76 to 1.38 ± 0.67 (p < 0.01).
The MTL/whole brain ratio also significantly decreased from 6.47 ± 6.48 to 4.59 ± 4.80 (p < 0.02).
Results suggest lecanemab treatment is associated with reduced brain volume, but clinical significance remains uncertain.
Longitudinal studies linking brain volume reduction with clinical outcomes are recommended.

Hasty Briefsbeta